Precivity-ApoE™

About C2N Diagnostics

C2N Diagnostics is a privately held, commercial-stage company providing advanced blood-based biomarker tests for Alzheimer's disease. Its core technology is a proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) platform used to detect amyloid pathology and other biomarkers with high accuracy. The company generates revenue through its CLIA lab services, has established key international partnerships, and plays a significant role in supporting clinical trials for disease-modifying therapies. C2N is positioned at the forefront of the rapidly growing market for accessible, blood-based neurodegenerative disease diagnostics.

Therapeutic Areas